Organizational Strategy - Sustainable Development - L'Oréal

2 L’OréaL - GrI DaTa SHEETS 2011
In €M 2010 2011
Operating profit 3,056.9 3,292.6
Products and financial charges excluding dividends received -35.6 -25.2
Sanofi dividends 283.8 295.6
Profit before tax, excluding non-recurring items 3,305.2 3,563.1
Tax on profits, excluding non-recurring items -931.9 -977.6
Minority interests -2.3 -2.5
Group net profit (excluding non-recurring items)* 2,370.9 2,582.9
Net profit per share** (e) 4.01 4.32
Group share of net profit 2,239.7 2,438.4
Diluted earnings per share after minority interests (e) 3.79 4.08
Diluted average number of shares 591,392,449 597,633,103
* Net profit, excluding non-recurring items, also excludes asset depreciation, restructuring costs, the effects of taxes and minority interests.
** group share per diluted share, excluding non-recurring items.
• The total cost of net financial indebtedness fell strongly again this year and stands at 25.2 million euros. This new reduction results in a considerable
lessening of its average debt.
• Dividends from Sanofi rose to 295.6 million euros, up by 4.2%.
• Tax on profits, excluding non-recurring items rose to 977.6 million euros, i.e. 27.4%, slightly down on 2010.
• The group share of net profit excluding non-recurrent items amounted to 2.5829 billion euros, up by 8.9%.
• The net profit per share, at €4.32, was up by 7.8%.
For 2011, after taking non-recurring items into account, i.e. a charge, net of taxes amounting to 144 million euros, the net profit is 2.4384 billion euros,
up by 8.9%.
CASH FLOW FROM OPERATIONS, BALANCE SHEET AND DEBT
The cash flow from operations was 3.2262 billion euros.
The need for working capital increased to 322 million, following two years when it had reduced in absolute terms. It is a return to a situation more in
line with changes to group business.
Investments, at 865.7 million euros, amounted to 4.3% of turnover.
after paying a dividend and acquisitions (Q-MED and Clarisonic), the group posted a net cash surplus of 504 million euros.
The balance sheet structure is very solid since, at the end of 2011, own capital made up 65.7% of the assets. The strengthening of own capital over
2010 results mainly from the profit allocated to reserves and the net re-valuation of Sanofi securities, valued at market price.
6/7